amer1 Antibody

What is AMER1 and why is it an important research target?

AMER1 (APC membrane recruitment 1) is a plasma membrane-associated protein of 1135 amino acids conserved in vertebrates. It is identical to the tumor suppressor WTX (Wilms Tumor gene on the X chromosome), which is mutated in a significant fraction of Wilms tumors and in the inherited disease osteopathia striata congenita with cranial sclerosis (OSCS) . AMER1 functions as a scaffold for the β-catenin destruction complex and serves as a negative regulator in Wnt signaling by inducing β-catenin degradation . Its dual role in both canonical Wnt pathway activation at the receptor level and downstream inhibition makes it a complex and important target for cancer research, developmental biology, and signal transduction studies.

What are the optimal tissue preparation methods for AMER1 antibody immunohistochemistry?

For optimal AMER1 antibody immunohistochemistry, tissue samples should undergo proper fixation and antigen retrieval. Based on validated protocols, TE buffer at pH 9.0 is recommended for antigen retrieval, though citrate buffer at pH 6.0 can serve as an alternative . Positive immunohistochemical detection has been confirmed in human kidney tissue and mouse stomach tissue . For paraffin-embedded sections, the following methodology yields optimal results:

• Deparaffinize and rehydrate tissue sections

• Perform heat-induced epitope retrieval with TE buffer (pH 9.0) for 15-20 minutes

• Block endogenous peroxidases with hydrogen peroxide

• Apply protein blocking solution to reduce non-specific binding

• Incubate with AMER1 primary antibody at dilutions ranging from 1:20 to 1:200 (optimal dilution should be determined empirically for each specific application)

• Apply appropriate detection system and counterstain

What are the key differences between AMER1 isoforms, and how do they affect antibody selection?

AMER1 exists in at least two identified splice variants with functional differences that researchers should consider when selecting antibodies. The full-length isoform (Amer1-S1) contains membrane-binding domains that enable plasma membrane association, while a shorter splice variant (Amer1-S2) lacks the membrane association domain . This structural difference significantly impacts function, as Amer1-S1 can stimulate LRP6 phosphorylation, whereas Amer1-S2 cannot .

When selecting antibodies, researchers should determine which isoform is relevant to their study. Antibodies targeting epitopes within the membrane-binding domains will detect only the full-length isoform, while those targeting common regions will detect both variants. This distinction is particularly important for studies investigating Wnt signaling at the membrane level, as only membrane-associated Amer1 participates in LRP6 phosphorylation and signalosome formation .

How can AMER1 antibodies be used to investigate the spatial and temporal dynamics of β-catenin destruction complex assembly?

AMER1 antibodies can be leveraged for sophisticated analyses of β-catenin destruction complex dynamics through several methodological approaches:

• Proximity Ligation Assays: AMER1 antibodies can be paired with antibodies against other destruction complex components (APC, Axin, β-catenin) to visualize and quantify protein-protein interactions at the single-molecule level within the plasma membrane.

• Immunofluorescence Co-localization Studies: AMER1 antibodies combined with membrane markers and other complex components can track the spatial organization of the destruction complex before and after Wnt stimulation.

• Immunoprecipitation with Phospho-specific Detection: AMER1 antibodies can be used for co-immunoprecipitation experiments followed by blotting with phospho-specific antibodies to measure how destruction complex assembly correlates with phosphorylation events.

Experimental data shows that AMER1 directly interacts with the armadillo repeats of β-catenin via a domain consisting of repeated arginine-glutamic acid-alanine (REA) motifs and assembles the β-catenin destruction complex at the plasma membrane by recruiting β-catenin, APC, and Axin/Conductin . Knockdown of AMER1 reduces Wnt-induced LRP6 phosphorylation, Axin translocation to the plasma membrane, and formation of LRP6 signalosomes, highlighting its essential role in Wnt signaling dynamics .

What methodological approaches can resolve contradictory findings regarding AMER1's role as both activator and inhibitor of Wnt signaling?

The literature presents an apparent paradox regarding AMER1's role in Wnt signaling - it appears to both activate and inhibit the pathway. To resolve these contradictory findings, researchers can employ the following methodological approaches:

• Temporal Analysis: Use pulse-chase experiments with AMER1 antibodies to track protein complex formation across different time points after Wnt stimulation. This can determine if AMER1 acts sequentially - first as an activator at the membrane level, then as an inhibitor downstream.

• Domain-Specific Functional Analysis: Employ antibodies targeting different AMER1 domains alongside domain deletion mutants to determine which regions are responsible for activation versus inhibition functions.

• Context-Dependent Signaling: Compare AMER1's function in sparse versus dense cell cultures using antibody-based detection methods, as research shows AMER1 function may be regulated by cell contacts .

• Phosphorylation State Discrimination: Use phospho-specific antibodies alongside AMER1 antibodies to determine how post-translational modifications affect AMER1's dual functionality.

How can researchers validate AMER1 antibody specificity for studies involving both wild-type and mutated forms associated with Wilms tumor?

Validating AMER1 antibody specificity for studies of both wild-type and mutated forms requires systematic approaches:

• Epitope Mapping: Determine precisely which regions of AMER1 the antibody recognizes and whether these regions are affected by common Wilms tumor mutations.

• Knockout/Knockdown Controls: Use CRISPR/Cas9 knockout or siRNA knockdown of AMER1 to create negative controls for antibody validation, confirming signal loss in these systems.

• Recombinant Protein Arrays: Test antibody reactivity against recombinant wild-type AMER1 and common mutant variants to establish detection profiles and potential cross-reactivity.

• Mutant-Specific Validation: For studies of specific mutations, perform Western blots comparing antibody reactivity in cells expressing wild-type versus mutant AMER1.

The following table summarizes recommended validation approaches for different experimental applications:

What are the optimal fixation and antigen retrieval protocols for AMER1 detection in different subcellular compartments?

AMER1 localization shifts between plasma membrane, cytoplasm, and nuclear compartments depending on cellular context and Wnt signaling status. Optimizing detection in each compartment requires specific protocols:

For plasma membrane AMER1 detection:

• Use mild fixation (2-4% paraformaldehyde for 10-15 minutes) to preserve membrane structures

• Apply gentle permeabilization (0.1-0.2% Triton X-100 for 5-10 minutes)

• Perform antigen retrieval with TE buffer at pH 9.0

• Use antibody dilutions at the higher concentration range (1:20-1:50)

For cytoplasmic and nuclear AMER1 detection:

• Use stronger fixation (4% paraformaldehyde for 15-20 minutes)

• Apply standard permeabilization (0.3% Triton X-100 for 10-15 minutes)

• Alternative antigen retrieval with citrate buffer at pH 6.0 may enhance nuclear epitope accessibility

• Use antibody dilutions in the middle-range (1:50-1:100)

When studying AMER1's dual subcellular roles, sequential or dual immunostaining approaches may be necessary to fully capture its distribution. Membrane localization of AMER1 is particularly important as it directly impacts its function in Wnt signaling—deletion or specific mutations of the membrane binding domain abolish membrane localization and abrogate negative control of Wnt signaling .

How can researchers design experiments to study the role of AMER1 in Wnt signaling using available antibodies?

Researchers investigating AMER1's role in Wnt signaling should consider the following experimental design approaches:

• Membrane Translocation Studies:

  • Co-immunostain for AMER1 and membrane markers (e.g., Na+/K+ ATPase)

  • Compare AMER1 localization before and after Wnt stimulation

  • Quantify membrane-associated versus cytoplasmic AMER1 fractions

• Complex Formation Analysis:

  • Use AMER1 antibodies for co-immunoprecipitation studies with β-catenin, APC, and Axin

  • Perform sequential immunoprecipitations to identify subcomplexes

  • Analyze how Wnt stimulation affects complex composition

• Signalosome Formation Visualization:

  • Combine AMER1 antibodies with LRP6 and Frizzled antibodies

  • Track signalosome formation using super-resolution microscopy

  • Quantify co-localization coefficients in the presence/absence of Wnt

• PtdIns(4,5)P2 Dependency Assessment:

  • Manipulate PtdIns(4,5)P2 levels using pharmacological agents (e.g., neomycin)

  • Monitor AMER1 membrane translocation and LRP6 phosphorylation

  • Compare wild-type AMER1 with PtdIns(4,5)P2-binding mutants

Research has demonstrated that overexpression of AMER1 promotes LRP6 phosphorylation, which requires interaction with PtdIns(4,5)P2 . AMER1 translocates to the plasma membrane in a PtdIns(4,5)P2-dependent manner after Wnt treatment and is required for LRP6 phosphorylation stimulated by application of PtdIns(4,5)P2 . These findings can be validated and extended using carefully designed antibody-based experiments.

How can researchers address non-specific binding when using AMER1 antibodies in tissues with high lipid content?

When working with AMER1 antibodies in lipid-rich tissues, non-specific binding can be problematic due to AMER1's natural affinity for membrane phospholipids. Researchers can implement the following strategies:

• Optimize Blocking Protocol:

  • Extend blocking time to 2-3 hours using 5-10% normal serum

  • Add 0.1-0.2% Triton X-100 to blocking buffer to reduce hydrophobic interactions

  • Consider adding 0.1% BSA and 0.05% Tween-20 to antibody diluent

• Lipid Extraction Pre-treatment:

  • For highly lipidic tissues, consider mild delipidation using brief (30-60 second) acetone treatment

  • Implement graded alcohol series pre-treatment to remove excess lipids

• Control Experiments:

  • Include peptide competition assays with the specific peptide used as immunogen

  • Perform parallel staining on AMER1-depleted samples (siRNA-treated or knockout)

  • Compare staining patterns using two different AMER1 antibodies recognizing distinct epitopes

• Adjust Antibody Concentration:

  • Titrate antibody concentration extensively (start with 1:200 and increase concentration only if needed)

  • Consider shorter incubation times at slightly higher concentrations rather than overnight incubation

When interpreting results, researchers should be aware that AMER1's membrane localization is functionally significant—it contains two N-terminal phosphatidylinositol(4,5)bisphosphate binding domains (M1 and M2) that are essential for its role in Wnt signaling regulation .

How should researchers interpret conflicting AMER1 antibody data between cell culture and tissue samples?

Discrepancies between AMER1 antibody staining patterns in cell culture versus tissue samples are commonly reported and may reflect biological realities rather than technical artifacts. To properly interpret such conflicting data:

• Consider Physiological Context:

  • AMER1 function appears to be regulated by cell contacts, with differential effects in sparse versus dense cultures

  • Tissue architecture and 3D organization may influence AMER1 localization in ways not recapitulated in 2D culture

• Evaluate Expression Levels:

  • Quantify relative AMER1 expression between tissues and cell lines using Western blot

  • Determine if differences in expression level affect localization patterns

  • Consider native versus overexpressed protein behaviors

• Isoform Analysis:

  • Determine which AMER1 isoforms are present in each system (Amer1-S1 vs. Amer1-S2)

  • The natural splice variant of AMER1 lacking the plasma membrane localization domain is deficient for Wnt inhibition

  • Use RT-PCR to identify which transcripts are expressed in each experimental system

• Methodological Reconciliation Approach:

  • If resources permit, prepare tissue-derived primary cells to bridge the gap between systems

  • Apply identical fixation/staining protocols to both systems

  • Consider developing 3D culture models that better recapitulate tissue architecture

The table below summarizes potential sources of discrepancy and recommended interpretative approaches:

How might AMER1 antibodies advance our understanding of its role in both Wnt signaling activation and inhibition?

AMER1 antibodies can be strategically employed to unravel the mechanistic basis of its apparently contradictory roles in Wnt signaling through several innovative research approaches:

• Spatial Proteomics:

  • Use AMER1 antibodies for proximity labeling techniques (BioID, APEX) to identify protein neighborhoods

  • Compare AMER1 interactomes at the membrane versus cytoplasmic compartments

  • Determine how these interaction networks change with Wnt pathway activation

• Temporal Resolution Studies:

  • Develop phospho-specific AMER1 antibodies to track its activation state

  • Perform time-course immunoprecipitations after Wnt stimulation

  • Map the sequential assembly/disassembly of AMER1-containing complexes

• Structure-Function Analysis:

  • Generate domain-specific antibodies targeting the REA motifs, APC-binding regions, and membrane-binding domains

  • Use these tools to determine which protein interactions occur simultaneously versus sequentially

  • Correlate structural interactions with functional outcomes in Wnt reporter assays

Research has shown that AMER1 stimulates LRP6 phosphorylation at the receptor level while also promoting β-catenin degradation downstream . These dual roles might be coordinated through precise spatiotemporal regulation—AMER1 binds CK1γ, recruits Axin and GSK3β to the plasma membrane, and promotes complex formation between Axin and LRP6, suggesting a scaffolding function that may change depending on cellular context .

What are the most promising approaches for developing antibodies that distinguish between wild-type and mutant AMER1 in clinical samples?

Developing antibodies that reliably distinguish between wild-type and mutant AMER1 would significantly advance both research and clinical applications. The most promising approaches include:

• Mutation-Specific Antibody Development:

  • Design peptide immunogens corresponding to common mutation hotspots in Wilms tumors

  • Produce antibodies that specifically recognize truncated forms resulting from frameshift mutations

  • Validate specificity using recombinant proteins and known mutation-positive tumor samples

• Conformational Epitope Targeting:

  • Develop antibodies recognizing three-dimensional epitopes that are disrupted by mutations

  • Use structural biology data to identify regions where mutations cause conformational changes

  • Engineer phage display libraries to select antibodies with the desired specificity

• Protein Function-Based Detection:

  • Generate antibodies against post-translationally modified regions absent in mutant forms

  • Develop antibodies recognizing AMER1 only when bound to specific partners (e.g., APC or β-catenin)

  • Create proximity-based detection systems where antibody pairs generate signal only for functional protein

The following table outlines mutation patterns in AMER1 and corresponding antibody development strategies:

AMER1 mutations play significant roles in Wilms tumors and osteopathia striata congenita with cranial sclerosis, making mutation-specific detection tools valuable for both research and potential diagnostic applications .

What are the critical considerations for researchers selecting AMER1 antibodies for their specific experimental applications?

When selecting AMER1 antibodies for specific experimental applications, researchers should consider several critical factors:

• Epitope Specificity: Determine whether the antibody targets regions involved in specific functions (membrane association, protein-protein interactions) and whether these regions are relevant to your research question.

• Isoform Recognition: Verify whether the antibody detects both major isoforms (Amer1-S1 and Amer1-S2) or is specific to one, as this will significantly impact experimental interpretation, particularly in Wnt signaling studies .

• Cross-Reactivity Profile: Confirm species reactivity, especially for comparative studies. Currently available antibodies show reactivity with human and mouse AMER1 .

• Application Validation: Ensure the antibody has been validated for your specific application. For instance, some antibodies may be optimized for IHC (at dilutions of 1:20-1:200) but not for other applications like Western blotting .

• Buffer Compatibility: Consider buffer requirements, particularly for membrane studies, as AMER1's interaction with PtdIns(4,5)P2 is sensitive to certain buffer components .

By carefully evaluating these factors, researchers can select the most appropriate AMER1 antibody for their specific experimental needs, ensuring reliable and reproducible results that advance our understanding of this multifunctional protein's role in development, disease, and cellular signaling.